Jump to start of content

ABIM call wait times may be longer than usual Expand/Collapse the ABIM alert.

Due to high volume, ABIM call wait times may be longer than usual. We know how busy you are, so we apologize for any inconvenience this may cause. You can always send us a message at abim.org/contact.

Coronavirus Updates Expand/Collapse the ABIM alert.

At ABIM we are actively monitoring the ongoing spread of coronavirus (COVID-19) and will post regular updates about any changes to scheduled assessments.
Scheduled for an assessment this year? ABIM is working with Pearson VUE to ensure your safety throughout your exam day. Learn more about what to expect at test centers.
Please follow the United States Centers for Disease Control and Prevention (CDC) for the most up-to-date information on the virus.

Breadcrumb trail:

Hematology Board Exam Committee

Expand All | Collapse All

Robert T. Means Jr., MD, Chair

Robert T. Means Jr., MDDr. Means, a board certified internist and hematologist, was the former Dean and presently Professor of Internal Medicine at the James H. Quillen College of Medicine, East Tennessee State University in Johnson City, Tennessee.

Before coming to Quillen, he was Executive Dean of the University of Kentucky College of Medicine. Other positions Dr. Means held at Kentucky included Senior Associate Chair of Internal Medicine, Interim Director of the Markey Cancer Center and Chief of the Medical Service at the Lexington VA Medical Center. He served as Director of the Hematology Oncology Division at the Medical University of South Carolina, and was on faculty at the University of Cincinnati and Vanderbilt.

Dr. Means is the Chair of the American Board of Internal Medicine Hematology Board Exam Committee. He is past President of the Southern Society for Clinical Investigation and a Fellow of the American College of Physicians. He is also an Associate Editor of the Journal of Investigative Medicine, and serves on editorial boards for the American Journal of the Medical Sciences, Blood Research, and International Journal of Hematology. He is on the Medical & Scientific Advisory Board of the Iron Disorders Institute.

Dr. Means received his bachelor's degree in biochemistry from Rice University in Houston, Texas. He earned his medical degree at Vanderbilt University in Nashville, Tennessee. He trained in internal medicine at Baylor College of Medicine Affiliated Hospitals in Houston, Texas, before returning to Vanderbilt for a fellowship in hematology.

As of May 2020, Dr. Means reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • Cambridge University Press, receiving compensation as an editor for Nutritional Anemia.
  • Lippincott Williams Wilkins/Wolters Kluwer, receiving royalties for the textbook, Wintrobe's Clinical Hematology, 12th and 13th editions.
  • Springer, receiving compensation as an editor for Anemia in the Young and Old: Diagnosis and Management.
  • UpToDate, receiving compensation as an author and editor.

Dr. Means serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Southern Society for Clinical Investigation, Executive Advisory Committee, compensation for lodging at annual retreat provided directly to hotel.
  • Iron Disorders Institute, Member of the Medical & Scientific Advisory Board, without compensation.
  • Aplastic Anemia & MDS International Foundation, speaker at patient education webinar, with compensation paid to Quillen College of Medicine, East Tennessee State University.

Lisa N. Boggio, MD

Dr. Lisa Boggio is Assistant Professor of Medicine in the Department of Medicine, Division of Hematology and Oncology, Section of Hematology. At Rush Medical College, Dr. Boggio is the clinical director of the Rush Hemophilia Treatment Center. This federally-funded center offers comprehensive treatment for children and adults with hemophilia, Von Willebrand disease, and other bleeding disorders, as well as a wide range of clotting disorders. She is also a co-Director of the Consultative Hematology Service.

Dr. Boggio has expertise in bleeding and thrombotic disorders, cytopenia, myeloproliferative disorders, and myelodysplastic disorders. She has authored numerous publications and was a recipient of the David Green-Hau Kwaan Teaching Award at Northwestern University. She is a member of the American Society of Hematology, the Hemophilia Foundation of Illinois, the National Hemophilia Foundation, the World Federation of Hemophilia, the International Society on Thrombosis and Haemostasis, the Hemophilia and Thrombosis Research Society, the American Association of Blood Banks, the American College of Physicians/American Society of Internal Medicine, the American Society of Clinical Apheresis and the Hemophilia and Thrombosis Research Society. and she has contributed to several committees within these societies.

She is a member of the board of directors and is Medical Director of Camp Warren Jyrch of the Hemophilia Foundation of Illinois. She is a guest reviewer for several journals, including the Thrombosis and Haemostasis, Drugs, Blood Coagulation and Fibrinolysis, Journal of the American Medical Association, The American Journal of Cardiology and Haemophilia.

Dr. Boggio graduated from the Chicago Medical School in 1993 and completed her residency in internal medicine and fellowship in hematology and oncology at Northwestern University.

As of October 2019, Dr. Boggio reported no external relationships.

Funding for clinical trial expenses and staff, paid to Rush University Medical Center, from the following companies:

  • Alnylam
  • Bayer
  • Novo Nordisk
  • OctaPharma
  • Sanofi
  • Takeda

Service on a research-related advisory board for the following companies, with and honoraria:

  • Novo Nordisk
  • OctaPharma
  • Sanofi

Dr. Boggio serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Bleeding Disorders Alliance Illinois, serving as medical director of bleeding disorders camp educational lectures for patient meetings, without compensation.

Kelly M. Davidson, MD

Kelly M. Davidson, MDDr. Davidson is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of Virginia (UVA), where she practices hematology at the Emily Couric Clinical Cancer Center. She was initially certified in internal medicine, medical oncology and hematology, and maintains her certification in hematology.

Dr. Davidson specializes in a variety of benign and malignant hematologic diseases, with a focus on cellular hematology. She sees patients with myeloproliferative and myelodysplastic disorders, red cell disorders including sickle cell disease, bone marrow failure syndromes, plasma cell dyscrasias, mast cell disorders and disorders of hemostasis and thrombosis. In addition to clinical practice, Dr. Davidson teaches in the second-year medical student course in hematology and plays an active role in resident and fellowship training at UVA. She previously practiced both hematology and oncology at Associates in Oncology/Hematology in Rockville, Maryland.

From 2015 through present, Dr. Davidson has been named to the list of Best Doctors in America. In 2016, she served on the American Board of Internal Medicine (ABIM) Standard Setting Panel for the Hematology Maintenance of Certification Exam (ABIM), and currently serves as a member of the ABIM Hematology Board Exam Committee. She has been a member of the American Society of Hematology since 2003.

Dr. Davidson received a biology degree summa cum laude from Georgetown University and her medical degree from Washington University in St. Louis. She completed internship and residency in internal medicine at Beth Israel Deaconess Medical Center in Boston and fellowship training in hematology and oncology at UVA.

As of September 2019, Dr. Davidson reported no external relationships.

Chancellor E. Donald, MD

Chancellor E. Donald, MDDr. Donald currently practices at Lourdes Oncology Associates in Lafayette, Louisiana. In 2010, he joined the practice and became Managing Partner in 2014. Additionally, at Our Lady of Lourdes Regional Medical Center, he functions as Medical Director of the oncology service line, a member of the Medical Executive Committee and as a Trustee on the Board of Directors.

Dr. Donald is board certified in Internal Medicine, Hematology and Medical Oncology. He serves on the American Board of Internal Medicine’s Hematology Exam Board Committee.

Dr. Donald advocates for patients with malignancies and hematologic disorders. He is currently President of the Louisiana Oncology Society. He has been appointed to the Board of Directors of the Community Oncology Alliance. In 2013, he was given the Spirit of Hope Award by the American Cancer Society. The American Society of Hematology (ASH) selected him for its Committee on Practice. He also holds the position of ASH’s alternate delegate to the American Medical Association’s House of Delegates. Since 2012, he has served as the Hematology Representative for Louisiana for the Medicare Carrier Advisory Committee (CAC). He served as co-chair of the 2017 annual CAC meeting at the American Society of Clinical Oncology headquarters and was again selected for that role for the 2018 annual meeting at the American Society of Hematology headquarters. For the 2017 Annual Meeting of the American Society of Hematology, he served as the clinical designee to the Program Committee.

Dr. Donald graduated magna cum laude from Florida A&M University and received his medical degree from the University of Miami School of Medicine. He completed his internship, residency and fellowship at Tulane University. He served as Chief Resident and Chief Fellow there and currently holds the position of Clinical Assistant Professor within Tulane’s Department of Hematology/Oncology.

As of August 2019, Dr. Donald reported the following external relationships:

Service on a research-related expert panel or advisory board for the following company, receiving honoraria:

  • Pfizer, for serving on an advisory board discussing the sequencing and use of tyrosine kinase inhibitors for epidermal growth factor receptor-mutated lung cancer.

Dr. Donald serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Standing Member of Committee on Practice; Alternate Delegate to the House of Delegates of the American Medical Association; receiving reimbursement for travel expenses.
  • Community Oncology Alliance, Board of Directors, Member, without compensation.
  • Taking Aim at Cancer in Louisiana Initiative, Chief Medical Officer, without compensation.
  • Louisiana Oncology Society, Immediate Past President, without compensation.

Morie A. Gertz, MD

Morie A. Gertz, MDDr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair of the Department of Medicine at the Mayo Clinic. He is board certified in Internal Medicine, Hematology and Medical Oncology.

Previously, Dr. Gertz served as Treasurer for the International Myeloma Society and as President of Mayo Staff Officers and Councilors. He was the Chair of the Mayo Personnel Committee. He currently serves on the American Society of Hematology Training Program Committee and the American Board of Internal Medicine Hematology Board Exam Committee.

He has been recognized with the 2014 Jan Waldenström Medal for Medical and Scientific Achievements in Waldenström's Macroglobulinemia and is a Mayo Distinguished Clinician. He has been recognized for his contributions in amyloidosis and Waldenström's macroglobulinemia. He has authored more than 500 peer-reviewed publications in the field and is a frequently invited speaker nationally.

Dr. Gertz is a master of the American College of Physicians. His undergraduate degree was awarded with highest distinction from Northwestern University, graduating Phi Beta Kappa. He received his medical degree cum laude from Loyola Medical School and was elected to Alpha Omega Alpha, the medical honor society. He completed a three-year medical residency at Rush Presbyterian St. Luke's Hospital in Chicago and was voted Resident of the Year for two of those years.

As of July 2019, Dr. Gertz reported the following external relationships:

Preclinical research, with funding for staff provided to the Mayo Clinic, from the following company:

  • Annexon Biosciences, for patient sera for antibody testing.

Funding for clinical trial expenses and staff, from the following companies:

  • Alnylam, for a trial of imRNA for familial amyloidosis, providing funding for staff, paid to Mayo Clinic.
  • Ionis, for a trial of IRNA for familial amyloidosis, providing funding for staff and expenses.
  • Millennium for a trial of bortezomib for amyloidosis AL, providing funding for staff, paid to Mayo Clinic.
  • Pfizer Pharmaceuticals, for a trial of tafamidis for cardiac amyloidosis, providing funding for staff, paid to Mayo Clinic.

Attendance at investigators' meetings, with compensation as listed from the following companies:

  • Millennium, to discuss a strategic planning model, receiving reimbursement for travel expenses and honoraria.
  • Novartis, for sales force education, receiving reimbursement for travel expenses and honoraria.
  • Onyx, receiving reimbursement for travel expenses and honoraria.

Service on data and safety monitoring boards for the following company, with honoraria:

  • AbbVie, for a Phase III trial of venetoclax.

Service on research-related expert panel or advisory board for the following company, with compensation as listed:

  • Celgene, to advise on medical content of lectures sponsored by the company, receiving reimbursement for travel expenses and honoraria.
  • Sandoz, to advise on use of biosimilars, receiving honoraria.

Industry-supported continuing medical education supported by the following, with compensation as listed:

  • Onyx, receiving reimbursement for travel expenses and honoraria.

Teaching in industry-sponsored satellite symposia with funding from the following company, with compensation as

  • Research to Practice, a medical education company that receives support from pharmaceutical companies, receiving reimbursement for travel expenses and honoraria.

Dr. Gertz serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • BMJ Point of Care, receiving compensation for creating online content.

Dr. Gertz serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Training Committee, receiving reimbursement for travel expenses.
  • Amyloidosis Support Network, receiving reimbursement for travel and other expenses associated with providing lectures to patients.
  • International Waldenstroms Macroglobulinemia Foundation receiving reimbursement for travel and other expenses associated with providing lectures to patients.

Elizabeth Hexner, MD

Elizabeth Hexner, MDDr. Hexner is a physician scientist with an interest in education and two major research interests in malignant hematology: the first is in cellular therapies and hematopoietic stem cell transplantation, and the second is in myeloproliferative neoplasms (MPN). Both have a translational focus and align with her clinical roles as Medical Director of the Center for Cellular Immunotherapies and as Director of the Penn MPN program. In MPN she has designed and executed preclinical studies of janus kinase (JAK) inhibitors and also used bioassays and correlative studies in MPN patients treated with JAK inhibitors focused on resistance.

Her work in MPN, cellular therapies, stem cell transplantation, primary cell systems and preclinical and clinical investigation allows me to intersect productively with basic science, transfusion medicine, regulatory, and clinical colleagues. In another major area of focus. Dr. Hexner serves as the Associate Director of the NIH CTSA-funded Masters in Translational Research program at the University of Pennsylvania, serving on the education, selection, and curriculum committees and overseeing a cohort of candidates as a programmatic mentor.

Dr. Hexner received her medical degree from Columbia University. She completed her residency at New York Presbyterian/Columbia University Medical Center and her fellowship at the Hospital of the University of Pennsylvania.

As of May 2020, Dr. Hexner reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to the University of Pennsylvania, from the following companies:

  • Blueprint Medicines, receiving funding for staff and expenses.
  • TMUNITY, receiving funding for salary support.

Cindy A. Leissinger, MD

Dr. Leissinger is Professor of Medicine and Clinical Professor of Pediatrics and Pathology at Tulane University in New Orleans, Louisiana, and is Chief of the Hematology/Oncology Division. She became Director of the Louisiana Comprehensive Hemophilia Care Center (now the Louisiana Center for Bleeding and Clotting Disorders) in 1992, and has remained in that position ever since. She is board certified in Internal Medicine and Hematology.

In addition to caring for patients with bleeding and clotting disorders, Dr. Leissinger oversees an active research program. She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.

Dr. Leissinger is a member of the American Board of Internal Medicine Hematology Board Exam Committee. Additionally, she is actively involved in the American Society of Hematology, the International Society on Thrombosis and Haemostasis, and the Hemostasis and Thrombosis Research Society.

Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at the National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.

As of August 2019, Dr. Leissinger reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Tulane University, from the following companies:

  • Biomarin, for a study of a FVIII gene therapy.
  • Roche, for a study of a new Factor VIII mimetic protein.

Industry-supported continuing medical education supported by the following company, with compensation for travel expenses and honoraria:

  • Genentech, for general educational talks on hemophilia.

Dr. Leissinger serves in a significant role with the following organization:

  • Hemostasis and Thrombosis Research Society, President-Elect, receiving no compensation.

Dr. Lessinger also reported that she serves on advisory boards for the following pharmaceutical companies, and receive honoraria for participation in advisory board meetings that are focused on bleeding disorders, mainly hemophilia and Von Willebrand disease: Takeda, Bayer, CSL Behring, Kedrion, Roche (Genentech), HemaBiologics, Uniqure, Spark Therapeutics.

Laura C. Michaelis, MD

Laura C. Michaelis, MDDr. Michaelis is an Associate Professor of Medicine at the Medical College of Wisconsin. She is the Associate Vice Chair of the Department of Medicine and serves as the Director of Inpatient Services for the Division of Hematology/Oncology. She is board certified in Hematology and her professional interests include clinical research in acute and chronic leukemias.

Previously, Dr. Michaelis was the director of the fellowship program at Loyola University Medical Center, where she worked as a general hematologist for seven years after finishing her fellowship. While practicing at Loyola, Dr. Michaelis became interested in physician-patient education and advocacy as well as peer-to-peer education. She co-chaired the Chicago MPN roundtable, an organization devoted to teaching patients and practitioners about the standard of care in this rare condition.

Dr. Michaelis is active in the American Society of Hematology, where she serves on the publications committee and communications committee and is the editor-in-chief of The Hematologist. She also serves on the Educational Committee for the Society of Hematologic Oncology and also serves on the American Board of Internal Medicine Hematology Board Exam Committee. She is a member of the ASH guidelines committee on leukemia in the elderly and continues to participate actively in patient-education forums, speaking nationally on myeloproliferative disorders to patient groups.

Dr. Michaelis did her fellowship in hematology and oncology at the University of Chicago and completed her internship and residency in internal medicine at the Brigham and Women’s Hospital in Boston. She graduated from Harvard Medical School in 2000. Before entering medical school, Dr. Michaelis was a newspaper and magazine reporter. She earned a Master of Journalism degree from Northwestern University and worked at news outlets throughout the country, including the MacNeill-Lehrer NewsHour, the Los Angeles Times and Congressional Quarterly.

As of May 2020, Dr. Michaelis reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Medical College of Wisconsin, from the following company:

  • Jazz, to receive funding for clinical trial staff, expenses, and salary support that will soon begin.

Work as an author or editor for following company, with compensation as listed:

  • American Society of Hematology, Editor-in-chief for The Hematologist, receiving honoraria and reimbursement for travel expenses. She also receives compensation for authorship.

Dr. Michaelis serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Speaker at national meeting, receiving reimbursement for travel expenses and honoraria.

Danielle A. Shafer, DO

Dr. Shafer is the Director of Hematology Research at Inova Schar Cancer Institute in Fairfax, VA where she practices. She has maintained her certifications in internal medicine, medical oncology and hematology.

Dr. Shafer specializes in the treatment of malignant hematologic disease with a focus on acute leukemia and aggressive lymphoma. She is also a strong advocate for clinical research and has been principal investigator of several Phase I trials. At Virginia Commonwealth University, she was Medical Director of the Clinical Trials Office at Massey Cancer Center. In addition to clinical practice and clinical research, she has been involved in medical education including the first-year medical student course in malignant hematology as well as formal resident and fellow education.

Dr. Shafer received an engineering degree from Michigan State University and her medical degree from Chicago Osteopathic Medical School. She completed internship and residency in internal medicine at Loyola University in May wood, Illinois and fellowship training in hematology and oncology at Fox Chase Cancer Center in Philadelphia, PA. She also received her masters degree in clinical research methods from Loyola University in Chicago.

As of September 2019, Dr. Shafer reported the following external relationships:

Dr. Shafer serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Leukemia & Lymphoma Society, Board Member, without compensation.